Pharmacology, Toxicology and Pharmaceutical Science
Lactoferrin
100%
Helicobacter Infection
66%
Placebo
66%
Malignant Neoplasm
66%
Chemotherapy
66%
Helicobacter Pylori
48%
Adverse Event
41%
Bevacizumab
40%
Stomach Cancer
35%
Disease
34%
Gastric Mucosa
33%
Inflammation
33%
Imatinib
33%
Gastrointestinal Stromal Tumor
33%
Alpha Fetoprotein
33%
Liver Cell Carcinoma
33%
Regorafenib
33%
Atezolizumab
33%
Chronic Hepatitis C
33%
Randomized Controlled Trial
33%
Epidermal Growth Factor Receptor 2
33%
Gamma Urogastrone
33%
Trastuzumab
33%
Overall Survival
23%
Immune Checkpoint Inhibitor
15%
Omeprazole
14%
Disease Exacerbation
13%
Gastritis
12%
Cisplatin
11%
Neoplasm
9%
Capecitabine
9%
Fluorouracil
9%
Alanine Aminotransferase
8%
Virus RNA
8%
Hepatitis C Virus
8%
Prothrombin
7%
Progression Free Survival
7%
Infection
6%
Liver Metastasis
6%
Peripheral Edema
6%
Eyelid Edema
6%
Interleukin 8
6%
Ammonium
6%
Chemotherapy Regimens
5%
Medicine and Dentistry
Neoplasm
75%
Endoscopy
70%
Narrow Band Imaging
66%
Helicobacter Pylori
66%
Endoscopic Submucosal Dissection
66%
White Light Endoscopy
33%
Stomach Cancer
33%
Pepsinogen
33%
Omeprazole
33%
Pancreas Islet Cell Tumor
33%
Sunitinib
33%
Metastatic Carcinoma
33%
Diagnosis
33%
Stomach Mucosa
33%
Leiomyosarcoma
33%
Endoscopic Ultrasound Guided Fine Needle Biopsy
33%
Eradication Therapy
33%
MALT Lymphoma
33%
Confocal Laser Scanning Microscopy
33%
Final Diagnosis
30%
Cancer Risk
25%
Odds Ratio
18%
Uterine Fibroid
16%
Stromal Tumor
16%
Diagnostic Accuracy
14%
Intestinal Metaplasia
12%
Spindle Cell Carcinoma
12%
Major Duodenal Papilla
12%
Endoscopic Biopsy
11%
Patient Referral
11%
Esophagogastroduodenoscopy
11%
Medical Oncology
9%
Gastrointestinal Stromal Tumor
8%
Multivariate Analysis
8%
Clinical Pathway
8%
Desmin
8%
Hysterectomy
8%
Tumor Cell
8%
Mitosis
8%
Distal Pancreatectomy
8%
Antiplatelet
7%
Surgery
5%
Lymphocyte
5%
Endoscopic Ultrasound
5%
Retrospective Study
5%
Stomach Lesion
5%
Gene Translocation
5%
Biopsy Sample
5%
Outcome Assessment
5%
Lamina Propria
5%
Fluorescence in Situ Hybridization
5%
Actin
5%
Tertiary Care
5%
Lymphoma Cell
5%
Selection Bias
5%
Keyphrases
Light Blue Crest
33%
Anti-PD-1 Antibody
33%
Regorafenib
33%
TAS-116
33%
Oral Inhibitors
33%
Efficacy Predictor
33%
Atezolizumab Plus Bevacizumab
33%
Second-look Endoscopy
33%
Well-differentiated Pancreatic Neuroendocrine Tumor
33%
Metastatic Gastric Cancer
33%
Randomized Placebo-controlled Trial
33%
Bovine Lactoferrin
33%
Chronic Hepatitis C
33%
Molecular Subtypes
33%
Feature Impact
33%
Full-endoscopy
33%
Gastrointestinal Subepithelial Lesions
33%
Endoscopic Ultrasound-guided
33%
GI Tumors
33%
Consensus Guidelines
33%
Epigenome Evolution
33%
Stage IV CRC
20%
Virological Response
19%
Mucin 1 (MUC1)
16%
Advanced Gastrointestinal Stromal Tumor
13%
Rs4072037
12%
Duodenal Papilla
12%
Uterine Myoma
11%
Metastatic Leiomyosarcoma
11%
Alanine Aminotransferase Level
9%
Hepatitis C Virus RNA
9%
Orally Administered
9%
Serum Alanine Aminotransferase
9%
Second Reader
9%
National Comprehensive Cancer Network
9%
Medical Oncology
9%
Subsequent Chemotherapy
8%
IV Infusion
8%
Cyst Size
8%
Eyelid Edema
6%
Macroscopic Complete Resection
6%
Peripheral Edema
6%
Small Molecule Tyrosine Kinase Inhibitors
6%
Spindle Cell Tumor
6%
Acquisition Rate
6%
Concordance Analysis
6%
Genome-wide Hypomethylation
6%
Progression-free
6%
Triple Therapy
6%
Liver Metastasectomy
6%
Forward-viewing
6%
Genetic Translocation
5%
Vertical Margin
5%
Methyl Transfer
5%